Broadcom's disappointing AI-chip guidance triggered a semiconductor sell-off, dragging down the Nasdaq while the S&P 500 and Dow Jones gained on sector rotation and value tailwinds. Healthcare stocks rallied with Eli Lilly and NovoCure posting strong gains. The pullback raises questions about AI stock valuations and whether the semiconductor sect...

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and ot...

Several biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive inte...

Soleus Capital Management increased its stake in Celcuity by 629,398 shares, bringing its total holdings to over 1.8 million shares valued at $180.36 million. This purchase elevated Celcuity to Soleus's third-largest holding, representing 6.7% of the fund's AUM. The move signals bullish confidence in the clinical-stage biotech company, which has ...

The FDA has approved Optune Pax, a portable non-invasive device developed by Novocure that delivers tumor treating fields (TTFields) to treat locally advanced pancreatic cancer. The device, which received Breakthrough Device designation, showed approximately two months improvement in overall survival when combined with standard chemotherapy in cl...